PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL

In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.

Episode metadata supplied by the publisher feed · Published Oct 22, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL

0:00 20:37

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of WTR Healthcare Happenings?

This episode is 20 minutes long.

When was this WTR Healthcare Happenings episode published?

This episode was published on October 22, 2025.

Can I download this WTR Healthcare Happenings episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!